A comeback for mescaline?
Scientists at universities including Johns Hopkins and NYU have made psilocybin their drug of choice as they seek remedies for a variety of mental ailments. The nonprofit Multidisciplinary Association for Psychedelic Studies is moving closer to gaining FDA approval for MDMA and talk therapy as a treatment for PTSD.
Yet mescaline has not been forgotten. A startup company called Journey Colab is preparing to start clinical trials to investigate the potential of mescaline to treat alcohol use disorder. Journey Colab and its founder, Jeeshan Chowdhury, have set aside equity in the company to recognize the contributions of indigenous people to psychedelic science.
Lucid News, a website about psychedelics, published my story about Journey Colab last week. Here’s the link.